The prospects for using bemiparin in prophylaxis and treatment of thromboses in oncology
Keyword(s):
Oncological patients have a high risk of thrombotic complications, which worsen the outcomes of antitumor treatment and is one of the leading causes of death. Low molecular weight heparins are the main drugs for the prevention and treatment of thrombotic complications in cancer patients. Zibor (bemiparin) is a second-generation low-molecular-weight heparin (LMWH) that has the lowest molecular weight (3600 Dalton), a half-life increased to 5.3 hours and the highest anti-Factor Xa activity ratio (8:1). In clinical trials, bemiparin has demonstrated high efficacy and safety for prophylaxis and treatment of thromboembolic complications.
2013 ◽
Vol 11
(3)
◽
pp. 366-375
◽
2013 ◽
Vol 30
(3)
◽
pp. 367-380
◽
1987 ◽
Keyword(s):
2009 ◽
Vol 20
(4)
◽
pp. 240-243
◽
2008 ◽
Vol 26
(15_suppl)
◽
pp. 9609-9609
2008 ◽
Vol 4
(1)
◽
pp. 63-71
◽